Insulin Degludec vs Insulin Aspart-Szjj — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Insulin Analog

Insulin Degludec

Brand: TRESIBA

First FDA approval: 2015-09-25

Insulin Analog

Insulin Aspart-Szjj

Brand: MERILOG

First FDA approval: 2025-02-14

Lowest NADACAcquisition cost floor across all NDCs

$9.02Per unit

—Per unit

Average NADACAcross all dosage forms and strengths

$13.60Up to $22.72

—

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$2.69BFull year

—Full year

Part D claims (CY24)Total fills, all strengths

3.5M1.2M beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$777Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

3Minimal friction

1Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

NoBrand-only